Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taysha Gene TherapiesTSHA -2.71%33 Quick Ratio is 17.76 as of Jun. 2026, which is 263% above its 10-year median of 4.89. GuruFocus rates TSHA with a GF Score™ of 33/100 and a GF Value™ of $0.53 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Taysha Gene Therapies ranks better than 90.7% on this metric.
Taysha Gene Therapies (NAS:TSHA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Taysha Gene Therapies Quick Ratio Related Terms
Taysha Gene Therapies Quick Ratio Historical Data
* Premium members only.
The historical data trend for Taysha Gene Therapies's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Taysha Gene Therapies's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taysha Gene Therapies Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Taysha Gene Therapies's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Taysha Gene Therapies's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taysha Gene Therapies (TSHA) has a Quick Ratio of 17.76 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Taysha Gene Therapies and its competitors. This is 263% above median its historical median of 4.89. Over the past decade, Taysha Gene Therapies' Quick Ratio has ranged from 0.10 to 36.17. According to the industry distribution chart, Taysha Gene Therapies ranks #131 out of 1409 companies in the Biotechnology industry, placing it in the top 9.3%.
Is Taysha Gene Therapies' Quick Ratio too high?
Taysha Gene Therapies' current Quick Ratio of 17.76 is 263% above median its 10-year median of 4.89. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 36.17. The Biotechnology industry median Quick Ratio is 3.60. Taysha Gene Therapies' value of 17.76 is 393.3% above this industry median. Based on the distribution chart, Taysha Gene Therapies ranks #131 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Taysha Gene Therapies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' Quick Ratio compare to KARD and GHRS?
According to the Biotechnology industry distribution chart, Taysha Gene Therapies ranks #131 out of 1409 companies for Quick Ratio. This places Taysha Gene Therapies in the top 9% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Taysha Gene Therapies' value of 17.76 is 393.3% above this benchmark. Historically, Taysha Gene Therapies' own Quick Ratio has ranged from 0.10 to 36.17 over the past decade. While the company's 10-year median is 4.89 vs. the industry median of 3.60, Taysha Gene Therapies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taysha Gene Therapies's current Quick Ratio of 17.76 is 393.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Taysha Gene Therapies and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taysha Gene Therapies's current Quick Ratio is 17.76, which is 263% above median its own 10-year median of 4.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.53, compared to a current price of $5.02 — trading 847.2% above its estimated fair value. The current Quick Ratio is 17.76, which is 263% above median its 10-year median of 4.89 and 393.3% above the Biotechnology industry median of 3.60. Taysha Gene Therapies' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current Quick Ratio is 17.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taysha Gene Therapies (TSHA) Overvalued in 2026?
Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued.
The current stock price of $5.02 is trading 847.2% above its estimated GF Value™ of $0.53.
GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.
Key valuation signals for TSHA:
Quick Ratio: 17.76 (263% above median its 10-year median of 4.89)
GF Value™: $0.53 vs. price of $5.02 (847.2% above fair value)
Industry Position: 393.3% above the Biotechnology median (#131 of 1409)
No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
33GF Score
Get the complete analysis for TSHA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSHA has been successfully added to your 
